SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis

SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis

Resistance to temozolomide (TMZ), the standard chemotherapy agent for glioblastoma (GBM), poses a major clinical challenge to GBM prognosis. Understanding the mechanisms of TMZ resistance can help to identify novel drug targets and more effective therapies. Recent studies suggest that bioenergetic a...

Full description

Bibliographic Details
Main Authors: Shuang Dai, Yuanliang Yan, Zhijie Xu, Shuangshuang Zeng, Long Qian, Lei Huo, Xuejun Li, Lunquan Sun, Zhicheng Gong
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-01-01
Series:Frontiers in Pharmacology
Subjects:
glioblastomas
temozolomide
resistance
SCD1
Akt signaling
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2017.00960/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2017.00960/full

Similar Items